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Abstract
Study Design: Guideline development.
Objectives: The objective of this study is to develop guidelines that outline how to best manage (1) patients with mild, moderate,
and severe myelopathy and (2) nonmyelopathic patients with evidence of cord compression with or without clinical symptoms of
radiculopathy.
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Methods: Five systematic reviews of the literature were conducted to synthesize evidence on disease natural history; risk factors
of disease progression; the efficacy, effectiveness, and safety of nonoperative and surgical management; the impact of preoperative
duration of symptoms and myelopathy severity on treatment outcomes; and the frequency, timing, and predictors of symptom
development. A multidisciplinary guideline development group used this information, and their clinical expertise, to develop
recommendations for the management of degenerative cervical myelopathy (DCM).
Results: Our recommendations were as follows: (1) “We recommend surgical intervention for patients with moderate and
severe DCM.” (2) “We suggest offering surgical intervention or a supervised trial of structured rehabilitation for patients with
mild DCM. If initial nonoperative management is pursued, we recommend operative intervention if there is neurological dete-
rioration and suggest operative intervention if the patient fails to improve.” (3) “We suggest not offering prophylactic surgery for
non-myelopathic patients with evidence of cervical cord compression without signs or symptoms of radiculopathy. We suggest
that these patients be counseled as to potential risks of progression, educated about relevant signs and symptoms of myelopathy,
and be followed clinically.” (4) “Non-myelopathic patients with cord compression and clinical evidence of radiculopathy with or
without electrophysiological confirmation are at a higher risk of developing myelopathy and should be counselled about this risk.
We suggest offering either surgical intervention or nonoperative treatment consisting of close serial follow-up or a supervised
trial of structured rehabilitation. In the event of myelopathic development, the patient should be managed according to the
recommendations above.”
Conclusions: These guidelines will promote standardization of care for patients with DCM, decrease the heterogeneity of
management strategies and encourage clinicians to make evidence-informed decisions.
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Summary of Recommendations
We recommend surgical intervention for patients with
severe DCM
Quality of Evidence: Moderate
Strength of Recommendation: Strong
We recommend surgical intervention for patients with
moderate DCM.
Quality of Evidence: Moderate
Strength of Recommendation: Strong
We suggest offering surgical intervention or a supervised
trial of structured rehabilitation for patients with mild
DCM. If initial nonoperative management is pursued,
we recommend operative intervention if there is neu-
rological deterioration and suggest operative interven-
tion if the patient fails to improve.
Quality of Evidence: Very low to low
Strength of Recommendation: Weak
We suggest not offering prophylactic surgery for non-
myelopathic patients with evidence of cervical cord
compression without signs or symptoms of radiculo-
pathy. We suggest that these patients be counseled as
to potential risks of progression, educated about rele-
vant signs and symptoms of myelopathy, and be fol-
lowed clinically.
Quality of Evidence: No identified evidence; based on
clinical expert opinion
Strength of Recommendation: Weak
Nonmyelopathic patients with cord compression and clin-
ical evidence of radiculopathy with or without electro-
physiological confirmation are at a higher risk of
developing myelopathy and should be counselled
about this risk. We suggest offering either surgical
intervention or nonoperative treatment consisting of
close serial follow-up or a supervised trial of struc-
tured rehabilitation. In the event of myelopathic devel-
opment, the patient should be managed according to
the recommendations above.
Quality of Evidence: Low
Strength of Recommendation: Weak
Introduction
Degenerative cervical myelopathy (DCM) is a progressive
spine disease and the most common cause of spinal cord dys-
function in adults worldwide.1 With the aging of the global
population, clinicians will be required to manage an increasing
number of patients with degenerative changes to their spine and
varying stages of myelopathy.2 Currently, there are no guide-
lines that outline how to best manage patients with mild
(defined as a modified Japanese Orthopedic Association
(mJOA) score of 15-17), moderate (mJOA ¼ 12-14), or severe
(mJOA  11) disease, or nonmyelopathic patients with evi-
dence of cord compression.3 This guideline provides
evidence-based recommendations to specify appropriate treat-
ment strategies for these four patient populations. The systema-
tic reviews aimed to (1) help identify patients at high risk of
neurological deterioration, (2) define the role of non-operative
and operative management in each patient group, and (3) deter-
mine which patients are most likely to benefit from surgical
intervention. The ultimate goal of these guidelines is to
improve outcomes and reduce morbidity in patients with DCM
by promoting standardization of care and encouraging
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clinicians to make evidence-informed decisions. An introduc-
tory article in this focus issue provides further background
information on DCM and summarizes the rationale, scope, and
specific aspects of care covered by this guideline. This article is
titled “A Clinical Practice Guideline for the Management of
Degenerative Cervical Myelopathy: Introduction, Rationale
and Scope.”
Methods
This guideline was developed under the auspices of AOSpine
North America and the Cervical Spine Research Society. A
multidisciplinary guideline development group (GDG) was
formed and consisted of clinicians from a broad range of spe-
cialties. The GDG was solely responsible for guideline develop-
ment and was editorially independent from all funding sources.
Members were required to disclose financial and intellectual
conflicts of interest (Appendix, Chapter 2). A guideline devel-
opment protocol, based on the Conference on Guideline Stan-
dardization (COGS) checklist,4,5 was created to outline the
rationale and scope of the guideline and to direct its develop-
ment. Systematic reviews were conducted based on accepted
methodological standards to summarize the evidence inform-
ing the recommendations. Details of specific methods used
for each topic are outlined in the individual reviews included
in this focus issue. Methods outlined by the Grading of Rec-
ommendation, Assessment, Development and Evaluation
(GRADE) Working Group were used to assess the overall
quality (strength) of evidence for critical outcomes.6,7 The
GRADE Guideline Development Tool was used to document
the process, rank the importance of outcomes, weigh the ben-
efits and harms of various options, and determine the strength
of recommendation.8-11 Methodologists with no financial or
intellectual conflicts of interest worked closely with clinical
authors to conduct the systematic reviews and provided meth-
odological expertise on the guideline development process.
Guideline development methods are provided in another arti-
cle included in this focus issue: “Guidelines for the Manage-
ment of Degenerative Cervical Myelopathy and Acute Spinal
Cord Injury: Development Process and Methodology.”
Clinical Recommendations
Part 1. Clinical Population: Patients With Severe DCM
Population Description: Patients with mJOA ¼ 0 to 11
Key Question: Should operative management be used to
treat patients with severe DCM?
Recommendation: We recommend surgical intervention
for patients with severe DCM
Quality of Evidence: Moderate
Strength of Recommendation: Strong
Evidence Summary
A systematic review of the literature was conducted to deter-
mine (1) the expected functional, disability and pain outcomes
following surgical intervention, (2) whether these expected
outcomes depend on preoperative disease severity or duration
of symptoms, and (3) what are the complications associated
with surgery. Thirty-two studies met inclusion criteria and were
summarized in this review: 9 prospective comparative studies,
4 randomized controlled trials, and 19 prospective case series.
Of these, 21 reported on change in JOA or mJOA (low/mod-
erately low risk of bias in 14, moderately high risk of bias in 7),
7 on neck disability index (NDI) (low/moderately low risk of
bias in 4, high/moderately high risk of bias in 3), 5 on Nurick
score (low/moderately low risk of bias in 2, high/moderately
high risk of bias in 3), and 5 on visual analog scale (VAS) (low/
moderately low risk of bias in 3, moderately high risk of bias in
2). The studies with moderately high risk of bias either had
undefined or poor follow-up rates (<80%).
Based on our results, pooled standard mean differences
showed a large effect for improvement in JOA or mJOA from
baseline at short-, medium-, and long-term follow-up: 6 to 12
months (1.92; 95% CI ¼ 1.41-2.43), 13-36 months (1.40; 95%
CI ¼ 1.12-1.67), and 36 months (1.92; 95% CI ¼ 1.14-2.69);
all Ps <.00001. Patients also exhibited clinically meaningful
improvements in the NDI and Nurick scores from baseline at
short-, medium-, and/or long-term follow-up: 6 to 12 months
(Nurick ¼ 1.42; 95% CI ¼ 1.11-1.74; NDI ¼ 18.02; 95% CI ¼
11.02-25.02), 13 to 36 months (Nurick¼ 1.06; 95% CI¼ 0.69-
1.43; NDI ¼ 19.71; 95% CI ¼ 14.01-25.42), and 36 months
(NDI ¼ 23.21; 95% CI ¼ 11.84-34.58); all Ps <.0001). Pooled
standard mean differences for the VAS were also large at all 3
follow-up periods: 6 to 12 months (32.74; 95% CI ¼ 18.39-
47.10), 13 to 36 months (32.55; 95% CI ¼ 21.37-43.72), and
36 months (40.00; 95% CI ¼ 37.01-42.99); all Ps <.0001.
The majority of studies included in the systematic review on
operative treatment consisted of patients with moderate to
severe myelopathy: mJOA/JOA (7.4-12.9), NDI (26.35-
55.20), Nurick (2.85-3.3), and VAS (32-71.6). Only 1 study
by Fehlings et al12 evaluated surgical outcomes in patients with
mild, moderate and severe disease using the criteria set by these
guidelines. Based on their results, patients with a mJOA<12
improved by 4.91 (95% CI ¼ 4.34-5.49) on the mJOA, by
12.53 (95% CI ¼ 8.05-17.02) on the NDI, and by 1.74 (95%
CI¼ 1.41-2.08) on the Nurick score. All of these changes were
statistically significant and exceeded reported minimal clini-
cally important differences (MCIDs) of these metrics.
The cumulative incidence of complications is low for
patients treated surgically for DCM (14.1%; 95% CI ¼
10.1%-18.2%). Specific complications include axial pain
(5.6%; 95% CI ¼ 3.8%-7.5%), laryngeal nerve injury/dyspha-
gia (2.2%; 95% CI ¼ 1.4%-3.0%), instrumentation/graft com-
plication (2.0%; 95% CI ¼ 1.3%-2.7%), C5 radiculopathy or
palsy (1.9%; 95% CI ¼ 1.4%-2.4%), pseudoarthrosis (1.8%;
95% CI ¼ 0.9%-2.6%), infection (1.5%; 95% CI ¼ 1.0%-
2.1%), adjacent segment disease (1.5%; 95% CI ¼ 0.3%-
2.7%), dural tear/cerebrospinal fluid leak (1.4%; 95% CI ¼
0.8%-1.9%), worsening of myelopathy (1.3%; 95% CI ¼
0.5%-2.1%), hematoma (0.9%; 95% CI ¼ 0.4%-1.4%), new
radiculopathy/palsy (not C5) (0.9%; 95% CI ¼ 0.0%-1.7%),
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neurologic deterioration (0.9%; 95% CI ¼ 0.3%-1.5%),
delayed wound healing (0.8%; 95% CI¼ 0.0%-1.7%), dyspho-
nia (0.7%; 95% CI ¼ 0.1%-1.2%), postoperative deformity
(0.5%; 95% CI ¼ 0.0%-1.2%), and bed sores (0.8; 95% CI ¼
0.0%-2.3%). Cumulative incidences of major complications
are also low: death (0.3%; 95% CI ¼ 0.0%-0.5%), stroke/tran-
sient ischemic attack (0.3%; 95% CI ¼ 0.0%-0.7%), esopha-
geal injury (0.0%; 95% CI ¼ 0.0%-2.9%), cardiopulmonary
events (3.3%; 95% CI ¼ 1.3%-5.3%), fracture (2.1%; 95%
CI ¼ 0.0%-4.5%), and reoperation/revision surgery (1.4%;
95% CI ¼ 0.6%-2.1%). Unfortunately, studies did not report
rates of complications based on preoperative myelopathy
severity.
A second systematic review was conducted to determine (1)
the change in function, pain and quality of life following struc-
tured non-operative treatment, (2) the variability of change in
function, pain and quality of life following different types of
structured nonoperative treatments, (3) the differences in out-
comes observed between certain subgroups (eg, baseline sever-
ity score, duration of symptoms), and (4) negative outcomes
and harms resulting from structured non-operative treatment.
Eight studies (1 randomized controlled trial, 3 prospective
cohort studies, and 4 retrospective cohort studies) met the
inclusion criteria and were summarized in this review. The
mean preoperative JOA scores ranged from 11.1 to 14.6; the
evidence from this review is therefore more applicable for
patients with moderate and mild myelopathy. Furthermore, the
GDG agreed that the results of nonoperative management are
less clinically relevant in the severe population.
In summary, there is moderate strength of evidence that
surgical intervention for DCM results in significant improve-
ments in clinical status as assessed by the mJOA or JOA at
short-, medium-, and long-term follow-up. Based on low
strength of evidence, rates of C5 radiculopathy or palsy and
infection were low following surgery for DCM. Furthermore,
very low strength of evidence suggested low pooled cumu-
lative incidences of dural tear/cerebrospinal fluid leak, wor-
sening of myelopathy, death, pseudoarthrosis, and implant
complications.
With regard to cost-effectiveness, 2 studies were identified
that evaluated the cost-utility of surgery in Canadian patients
enrolled in the AOSpine North America and/or International
studies. The first study (based on the North America study)
estimated the cost of surgery to be $21 066.44, with an incre-
mental cost-utility ratio (ICUR) of $32 916 per quality-adjusted
life year (QALY).13 A second study by Witiw et al14 (based on
the North America and International studies) conducted a more
rigorous cost-utility analysis using a 2-arm, Markov State Tran-
sition model where values for subjects undergoing surgery
were compared with estimated counterfactual outcomes of ini-
tial conservative management.14 In a primary model, the life-
time ICUR was determined to be $11 496/QALY gained for
surgical intervention, an estimate considered very cost-
effective according to criteria defined by the World Health
Organization (WHO). Further testing using a Monte Carlo
probabilistic sensitivity analysis revealed that 97.9% of
estimates fell within the WHO threshold, suggesting robustness
to variability in the parameter estimates. To supplement this
testing, a highly conservative assumption that individuals
undergoing initial nonoperative management would not expe-
rience any neurologic decline over their lifetime was added to
the model. In this scenario, the ICUR was calculated as
$20,548/QALY gained with 94.7% of estimates falling within
the WHO threshold; this finding further supports the cost-
effectiveness of surgical intervention. Unfortunately, these
analyses only explored the cost-effectiveness of surgery in
Canada and did not stratify their samples based on preoperative
myelopathy severity. This lack of generalizable evidence on
cost-effectiveness highlights a significant knowledge gap in
the literature; as a result, much of the discussion related to
resource requirements was based on professional opinion.
Rationale for Recommendation
The outcomes most critical for decision-making were change in
mJOA or JOA following surgery and rates of major complica-
tions. Major complications were defined as any surgery-related
adverse event that resulted in permanent morbidity, prolonga-
tion of hospital stay, or reoperation. The GDG agreed that the
results from the systematic review on nonoperative treatment
are less relevant to answer this question as most studies did not
evaluate outcomes in severe patients. The majority of the GDG
selected that the overall certainty of the evidence was moderate
given the large effect size of the pooled estimate from several
prospective studies.
The GDG believed that there was no important uncertainty
or variability about how much key stakeholders value the main
outcomes. Patients and clinicians would similarly value
improvement in functional status and a low risk of complica-
tions. Although the cost-effectiveness of surgery in these
patients is largely unknown, the GDG agreed that payers would
also value these main outcomes due to a likely reduction in
future management costs and financial burden.
The GDG agreed that the anticipated desirable effects (ie,
improved mJOA or JOA) were probably large and the antici-
pated undesirable effects (ie, treatment complications) were
probably small. Pooled standard mean differences showed a
large effect for improvement in functional status and disability
from baseline at short-, medium-, and long-term follow-up.
Furthermore, the rates of overall complications and of major
complications are low following surgery in this population. The
GDG acknowledges that the studies included in the systematic
review on operative treatment did not stratify their sample
based on preoperative myelopathy severity and that the risk
of complications may be slightly higher in patients with more
extensive degenerative pathology. Given these explanations,
the GDG agreed that the desirable effects are probably large
relative to the undesirable effects.
In the absence of evidence, the GDG used their clinical
expertise to discuss the resources required to surgically manage
patients with severe myelopathy. Although the GDG confirmed
the resources are probably not small, they also agreed that
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surgery may result in substantial cost savings due to long-term
improvements in quality of life, impairment, and disability. As
a result, the majority of the GDG (n ¼ 14) agreed that the
incremental cost is probably small relative to the net benefit
of surgery. Twelve members, however, argued that, in the
absence of evidence on cost-effectiveness, the cost-benefit
ratio is uncertain.
The GDG believed that a recommendation for surgery in
patients with severe myelopathy would probably reduce health
inequities; this decision was made under the assumption that
policy makers would fund initiatives to ensure patients with
severe myelopathy have improved access to surgical interven-
tion. The GDG agreed that the option of surgery would prob-
ably be acceptable to the majority of stakeholders due to
anticipated positive outcomes, a low risk of complications
and a likely reduction in overall management costs (probably
yes¼ 16, yes¼ 11). Finally, the option of surgical intervention
for patients with severe myelopathy is probably feasible to
implement (probably yes ¼ 12, yes ¼ 11); potential barriers
include an accurate diagnosis of myelopathy, a timely referral
for surgical consultation, patient access to care and high costs.
Considering all these factors, the GDG voted that the desir-
able consequences probably outweigh the undesirable conse-
quences in most settings (probably outweigh¼ 16, outweigh¼
9); this led to the formation of a strong recommendation for
surgery in patients with severe myelopathy.
Part 2. Clinical Population: Patients With Moderate DCM
Population Description: Patients with a mJOA¼ 12 to 14
Key Questions: Should operative management be used to
treat patients with moderate DCM?
Recommendation: We recommend surgical intervention
for patients with moderate DCM.
Quality of Evidence: Moderate
Strength of Recommendation: Strong
Evidence Summary
The evidence used for this recommendation was derived from
the systematic reviews on the efficacy and safety of nonopera-
tive and surgical management for the treatment of DCM.
Pooled mean improvements on the mJOA or JOA, Nurick,
NDI, and VAS following surgery are provided in the evidence
summary for part 1. Unfortunately, only 1 study by Fehlings
et al12 compared surgical outcomes between patients with mild,
moderate, and severe disease using the criteria set by this
guideline. Based on their results, patients with a mJOA
between 12 and 14 improved by 2.58 (95% CI ¼ 2.07-3.09)
on the mJOA, by 9.79 (95% CI ¼ 5.90-13.68) on the NDI, and
by 1.51 (95% CI ¼ 1.22-1.81) on the Nurick score. All these
changes were statistically significant and exceeded the reported
MCIDs for these metrics. Cumulative incidences of surgical
complications are also low and are reported in part 1. Unfor-
tunately, studies did not report rates of complications based on
preoperative myelopathy severity.
The systematic review on operative management also eval-
uated whether surgical outcomes were influenced by duration
of symptoms or preoperative disease severity. Three studies
evaluated differences in functional recovery based on the
mJOA or JOA between patients with varying duration of symp-
toms (12 and >12 months; <6, 6-12, >12 months).15-17 Based
on their results, the degree of improvement was not signifi-
cantly different between these patient subgroups. In contrast,
a fourth study reported that a longer duration of symptoms was
associated with reduced odds of achieving a mJOA score 16
at 1-year follow-up (odds ratio [OR] ¼ 0.78, 95% CI ¼ 0.61-
0.997, P ¼ .048).18 Four studies evaluated the relationship
between preoperative myelopathy severity and postoperative
neurological outcomes.12,18-20 In a study by Fehlings et al,12
patients with severe myelopathy (mJOA<12) demonstrated the
greatest improvement (4.91; 95% CI ¼ 4.34-5.49) on the
mJOA, while patients with mild disease (mJOA  15)
improved the least (1.29; 95% CI ¼ 0.70-1.87).12 Conversely,
Chibbaro et al19 reported that a similar percentage of patients
with either moderate (mJOA¼ 10-13) or severe (mJOA¼ 5-9)
myelopathy exhibit neurological improvement on the mJOA
score. Two other studies determined that patients with more
severe myelopathy are less likely to achieve a score 16 or a
postoperative improvement of 2 or more points on the
mJOA.18,20
In the systematic review on non-operative treatment, the
mean preoperative JOA scores ranged from 11.1 to 14.6.
Response to treatment was minimal, with change scores rang-
ing from 0 to 2.3. Only a single study by Matsumoto et al21
reported a mean change in JOA score of 2 points at final
follow-up (mean ¼ 47 months); their sample, however, only
consisted of patients with myelopathy secondary to soft disc
herniation. The proportion of patients who converted to surgery
following failed nonoperative care ranged from 23% to 54%.
The GDG agreed that the results from the systematic review on
nonoperative management are less relevant in patients with
moderate myelopathy and that these outcomes are not critical
for decision making.
In summary, there is moderate strength of evidence that sur-
gical intervention for DCM results in significant improvements
in clinical status as assessed by change in mJOA or JOA scores
at short-, medium-, and long-term follow-up. Based on low
strength of evidence, rates of C5 radiculopathy or palsy and
infection were low following surgery for DCM. Furthermore,
very low strength of evidence reported low pooled cumulative
incidences of dural tear/cerebrospinal fluid leak, worsening of
myelopathy, death, pseudoarthrosis, and implant complications.
It is also crucial to consider important predictors of out-
comes when devising appropriate treatment strategies. Based
on a study by Tetreault et al,18 the odds of achieving a post-
operative mJOA score 16 (1) decreased by 22% (OR ¼ 0.78,
95% CI ¼ 0.61-0.997, P ¼ .048) when a patient moved from a
shorter to a longer duration of symptoms group (3 months; >3
but 6 months; >6 but 12 months; >12 but 24 months; >24
months) and (2) were 1.22 times greater (OR¼ 1.22; 95% CI¼
1.05-1.41, P ¼ .0084) for every 1-point increase in
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preoperative mJOA. Furthermore, patients with more severe
preoperative impairment were less likely to exhibit a post-
operative improvement of 2 or more points on the mJOA scale
at 18-months follow-up (OR: 0.72; 95% CI¼ 0.66-0.92).20 The
rationale behind this finding is that severe and long-standing
compression of the spinal cord may result in histological dam-
age that cannot be reversed through decompression. In contrast,
moderate strength of evidence suggested that the improvement
in mJOA score from baseline is smaller for patients with mild
myelopathy (1.29; 95% CI ¼ 0.70-1.87) preoperatively than
those with moderate (2.58; 95% CI ¼ 2.07-3.09) or severe
(4.91; 95% CI¼ 4.34-5.49) impairment. This association, how-
ever, likely reflects the ceiling effect of the mJOA and the fact
that patients with a lower mJOA have larger room for improve-
ment. Finally, a recent study by Tetreault et al22 indicated that
patients with severe myelopathy must make larger gains (3
points) to achieve a MCID on the mJOA than patients with
moderate (2 points) or mild (1 points) disease. These results
indicate that patients should be operated on in a timely fashion
and before they progress to a more severe disease state.
Rationale for Recommendation
The voting for each question in the “evidence-to-
recommendation” framework was similar to the results pre-
sented in part 1 on severe myelopathy. The exception was that
there was more uncertainty with regard to whether the incre-
mental cost of surgery in moderate patients was small relative
to the net benefit (uncertain ¼ 12, probably yes¼ 10, yes¼ 2).
This uncertainty arises from the lack of evidence on the cost-
effectiveness of surgical intervention in varying myelopathy
severities; however, given that surgery significantly improves
function and reduces disability, there may be substantial cost
savings as these patients may require less future care and be
able to return to work.
The justifications for selecting these answers were also sim-
ilar to those presented in part 1. In addition to the efficacy and
safety of surgery, the associations between outcomes and dura-
tion of symptoms and preoperative myelopathy severity were
also considered when weighing the desirable and undesirable
effects. Patients with more severe myelopathy and a longer
duration of symptoms are less likely to achieve a score 16
on the mJOA. As a result, it is favorable to operate in a timely
fashion and before the patient progresses to a more severe
disease state.
Considering all these factors, the GDG voted that the desir-
able consequences probably outweigh the undesirable conse-
quences in most settings (probably outweigh¼ 20, outweigh¼
5); this led to the formation of a strong recommendation for
surgery in patients with moderate myelopathy.
Part 3. Clinical Population: Patients With Mild DCM
Population Description: Patients with mJOA 15 to 17
Key Questions: (1) Should nonoperative management be
used to treat patients with mild DCM? (2) Should
operative management be used to treat patients with
mild DCM?
Recommendation: We suggest offering surgical interven-
tion or a supervised trial of structured rehabilitation for
patients with mild DCM. If initial nonoperative man-
agement is pursued, we recommend operative inter-
vention if there is neurological deterioration and
suggest operative intervention if the patient fails to
improve.
Quality of Evidence: Very low
Strength of Recommendation: Weak
Evidence Summary
The GDG agreed it was important to consider the following
when developing a recommendation for the treatment of mild
myelopathy: (1) disease natural history; (2) the comparative
effectiveness of nonoperative versus operative intervention;
(3) the change in impairment, disability, and quality of life
following operative and nonoperative treatments; (4) the asso-
ciated risks of surgical and non-operative management; and (5)
important predictors of outcomes and disease progression.
Furthermore, patient preferences must be taken into account
as patients with mild symptoms may be hesitant to consent to
surgery.
Four systematic reviews were conducted to summarize the
evidence required for this guideline. In 2013, Karadimas et al23
published a systematic review on the natural history of DCM
and on important predictors of disease progression. This review
was updated for the purpose of this guideline and expanded to
include data on the rate of hospitalization due to spinal cord
injury in patients with myelopathy. Based on their results, there
was moderate evidence from 2 small prospective and 4 retro-
spective observational studies that 20% to 62% of patients with
symptomatic myelopathy deteriorate by at least 1 point on the
JOA at 3 to 6 years after initial assessment.23 Furthermore,
patients with DCM increasingly worsen at performing activi-
ties of daily living at 1-year (6%), 2-year (21%), 3-year (28%)
and 10-year (56%) follow-up. Finally, the rate of hospitaliza-
tion due to spinal cord injury is 4.8 per 1000 person-years in
patients with myelopathy secondary to ossification of the pos-
terior longitudinal ligament (OPLL) and significantly higher
than the rate in a healthy population (0.18 per 1000 person-
years) (hazard ratio [HR] ¼ 32.2; 95% CI ¼ 10.4-99.0). The
rate of spinal cord injury in individuals with CSM is 13.9 per
1000 person-years. Overall, the GDG agreed these rates are low
and less important for driving the recommendation for mild
patients.
A systematic review by Rhee et al24 aimed to define the role
of nonoperative treatment in patients with DCM by evaluating
the comparative effectiveness and safety of nonoperative ver-
sus operative management. Furthermore, Rhee et al24 also
examined the relationship between minor traumatic events and
worsening of myelopathy. This review was updated for the
purpose of this guideline and also presented information on the
relative hazard of spinal cord injury in patients treated
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nonoperatively versus surgically. The majority of conclusions
for this review were derived from a single randomized con-
trolled trial by Kadanka et al.25 This randomized controlled
trial reported that, in patients with “milder” myelopathy
(mJOA  12), (1) there was no difference in mJOA scores at
1-, 2-, 3- and 10-year follow-up between patients that received
operative versus nonoperative care; (2) surgery resulted in a
slower 10-m walk test than nonoperative treatment; and (3)
there was no difference between treatment groups in the pro-
portion of patients with worsened or improved clinician-based
or patient reported daily activity scores (low level evi-
dence).25,26 However, no improvements in the mJOA were
observed in the operative cohort of this trial, which differs from
the results reported in other series of myelopathic patients
undergoing surgical decompression12,19,27-34; this may partially
explain their finding of no difference between treatment
groups. Finally, based on low level evidence, rates of hospita-
lization for subsequent spinal cord injury were significantly
higher in patients undergoing initial conservative treatment
compared to those managed operatively (HR (ref ¼ operative
treatment) ¼ 1.57; 95% CI ¼ 1.11-2.22, P ¼ .011).
Given the paucity of comparative effectiveness studies, we
conducted 2 additional systematic reviews to evaluate the
change in impairment, quality of life and disability following
nonoperative and operative treatments. It is important to inter-
pret the results of these studies in terms of the MCID of various
assessment tools. Based on a study by Tetreault et al,22 the
overall MCID of the mJOA is between 1.11 and 2.0 and varies
by myelopathy severity (severe ¼ 3 points, moderate ¼ 2
points, mild ¼ 1 point). The MCID for the NDI in a degenera-
tive spine population is 7.5. Although the MCID of the Nurick
scale has not been defined, a 1-grade change likely reflects
substantial improvement in impairment.
The studies included in the systematic review on structured
nonoperative treatment consisted mostly of patients with mod-
erate myelopathy (range of mJOA between 11.1 and 14.6); no
studies were identified that discussed outcomes in only patients
with mild myelopathy. Types of structured nonoperative treat-
ment varied across studies and were not well defined; treat-
ments included bed rest, cervical traction, cervical
immobilization, thermal therapy, physical therapy, and/or non-
steroidal anti-inflammatory drugs. Based on very low-level
evidence, there were no statistically significant differences
between mJOA or JOA scores at baseline and following struc-
tured nonoperative treatment. Improvements on the mJOA or
JOA did not exceed the MCID (0-2.3) for this metric except in
the study by Matsumoto et al.21 The greatest reported gain in
functional status following nonoperative care was reported in
studies involving patients with myelopathy due to soft disc
herniation and dynamic cervical myelopathy. These etiologies
might be expected a priori to respond better to nonoperative
care, since soft disc herniation may spontaneously regress, and
immobilization may at least temporarily decrease cord irrita-
tion if the primary mechanism of compression is dynamic
rather than static. In contrast, nonoperative treatment had less
effect in patients with DCM due to static spinal cord
compression, or etiologies that do not tend to regress sponta-
neously over time. Furthermore, the proportion of patients who
underwent surgical intervention following failed structured
nonoperative treatment ranged from 23% to 54%.
In a systematic review on the efficacy of operative treatment,
only 1 study by Fehlings et al18 evaluated surgical outcomes in
patients with mild, moderate and severe disease using the criteria
set by this guideline. Based on their results, patients with a pre-
operative mJOA 15 to 17 improved by 1.29 (0.70-1.87) on the
mJOA, by 12.05 (7.76-16.34) on the NDI and by 1.54 (1.22-1.86)
on the Nurick scale. All of these changes were statistically sig-
nificant and exceeded the reported MCID for these metrics. The
cumulative incidence of complications is also low for patients
treated surgically for DCM. Rates of specific complications are
reported in part 1; unfortunately, studies did not report rates of
complications based on preoperative myelopathy severity.
These 2 systematic reviews also aimed to determine whether
outcomes differ in various subgroups (eg, based on baseline
severity score or duration of symptoms). In a study on nono-
perative treatment by Fukui et al,35 80% of patients with a
duration of symptoms less than 3 months improved by1 point
on the JOA, whereas only 46% of patients with a duration of
symptoms greater than 3 months exhibited this gain in func-
tional status. Furthermore, a retrospective study by Li et al36
reported a significant correlation between JOA recovery rate
and disease duration in a combined nonoperative and surgical
cohort (R ¼ 0.888, P < .01).
In the systematic review on operative treatment, low-level
evidence suggested that the odds of achieving a postoperative
mJOA 16 decreased by 22% (OR ¼ 0.78; 95% CI ¼ 0.61-
0.997; P¼ .048) when a patient moved from a shorter to longer
duration of symptoms group (3 months; >3 but 6 months;
>6 but 12 months; >12 but 24 months; >24 months).
Furthermore, baseline severity score was also associated with
postoperative outcomes: (1) the odds of achieving an optimal
outcome (mJOA  16) were 1.22 times greater (OR ¼ 1.22;
95% CI ¼ 1.05-1.41, P ¼ .0084) for every 1-point increase in
preoperative mJOA and (2) patients with more severe preo-
perative impairment were less likely to exhibit a postoperative
improvement of 2 or more points on the mJOA scale at 18-
months follow-up (OR ¼ 0.72; 95% CI ¼ 0.66-0.92). In con-
trast, moderate strength of evidence suggested that the
improvement in mJOA score from baseline is smaller for
patients with mild myelopathy (1.29; 95% CI ¼ 0.70-1.87)
preoperatively than those with moderate (2.58; 95% CI ¼
2.07-3.09) or severe (4.91; 95% CI ¼ 4.34-5.49) impairment.
This association, however, likely reflects the ceiling effect of
the mJOA and the fact that patients with a lower mJOA have
larger room for improvement.
Rationale for Recommendation
To develop a final recommendation, 2 key questions were
addressed: (1) Should nonoperative treatment be used to man-
age patients with mild DCM? (2) Should operative treatment be
used to manage patients with mild DCM?
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For the question on nonoperative treatment, the outcomes
most critical for decision making were change or improvement
in mJOA, rate of conversion to surgery, disease natural history
and incidence of hospitalization for spinal cord injury or severe
disability following a traumatic event. The GDG agreed that
the overall certainty of the evidence was either very low (n ¼
14) or low (n ¼ 10). The majority of studies that directly
answered this question were retrospective case series. A single
randomized controlled trial by Kadanka et al25,26 included a
heterogeneous population and did not use the same cutoff for
mild myelopathy as this guideline (mJOA  12 instead of
mJOA  15). Another limitation in the current body of evi-
dence is that “nonoperative management” was not uniformly
defined and consisted of a wide variety of treatments, including
medication, immobilization, and physical therapy.
The majority of the GDG (n ¼ 10) agreed that there was
probably no important uncertainty or variability about how
much stakeholders value the main outcomes. Eight members,
however, argued that there was possibly important uncertainty
or variability. Patients and clinicians would similarly value the
main outcomes: improvement in functional status, prevention
of disease progression and reduced risk of spinal cord injury. In
contrast, it is uncertain how much payers would value some of
these main outcomes given the lack of studies that discuss the
cost-effectiveness of nonoperative management in patients
with mild myelopathy. These values were assessed through
discussion among the GDG and based primarily on expert
opinion.
Fourteen members of the GDG agreed that the anticipated
desirable effects were probably not large (n¼ 14). Based on the
results from 5 studies, patients do not achieve clinically signif-
icant improvements on the mJOA or JOA following various
types of nonoperative treatments. Nine members, however,
were uncertain whether the anticipated desirable effects were
large; their rationale was that the studies that evaluated the
efficacy of nonoperative treatment did not stratify their sample
based on myelopathy severity.
The GDG was uncertain as to whether the anticipated unde-
sirable effects were small. The undesirable effects of nonopera-
tive treatment include disease progression, suboptimal
outcomes and hospitalization for spinal cord injury. Conver-
sion to surgery was not considered an undesirable effect as this
may reflect patient or clinician preferences. Based on the evi-
dence (1) 20% to 62% of symptomatic patients progress if not
treated surgically, (2) improvements in outcomes are subopti-
mal as they do not exceed the MCID of various metrics, and (3)
the incidence of hospitalization for spinal cord injury is higher
in patients treated conservatively than those managed opera-
tively (HR (ref ¼ operative treatment) ¼ 1.57; 95% CI ¼ 1.11-
2.22; P ¼ .011). Despite this evidence, the GDG were still
uncertain as these results were derived from studies that
included patients with varying myelopathy severities. Further-
more, the GDG was uncertain whether the desirable effects
were large relative to the undesirable effects.
In the absence of evidence, the GDG used their clinical
expertise to discuss the resources required to manage patients
nonoperatively. The group agreed that the resources required
for non-operative management are uncertain and likely vary
based on the type of non-operative management. For example,
the “rigorous” treatment protocol defined by Yoshimatsu
et al37 likely requires substantial resources as it consists of 3
to 4 hours of continuous cervical traction per day for 1 to 3
months, combined with immobilization by cervical orthosis,
exercise therapy, drug therapy and thermal therapy. Follow-
up monitoring may also involve significant resources.
The majority of the GDG were also uncertain on the impact
of a recommendation for nonoperative management on health
inequities, as well as the acceptability of this option to key
stakeholders. This uncertainty likely arises from the uncer-
tainty surrounding the relative size of desirable versus undesir-
able effects and the lack of data on the cost-effectiveness of
various interventions. The option of nonoperative management
for the treatment of mild myelopathy is probably feasible to
implement; however, potential barriers include access to care,
the requirement for patients to independently fund their treat-
ment, and an accurate and timely diagnosis of myelopathy.
Considering all these factors, the GDG agreed that the desir-
able and undesirable consequences are closely balanced or
uncertain; this led to the formation of a suggestion of nono-
perative treatment as an option for the management of patients
with mild myelopathy. Patient preferences are important con-
siderations in the decision-making process, as patients with
mild symptoms may be hesitant to undergo surgery and prefer
to pursue an initial trial of nonoperative treatment.
For the question on operative treatment, the outcomes most
critical for decision making were change in mJOA or JOA and
risk of major complications. It is also important to consider the
impact of duration of symptoms and preoperative myelopathy
severity on surgical outcomes. The GDG agreed that the overall
certainty of the evidence was low. Although there is moderate
evidence that suggests surgery results in clinically meaningful
improvements, only 1 study stratified their population based on
preoperative myelopathy severity. Furthermore, the heteroge-
neity of the patient sample across studies further reduces our
certainty in the overall evidence.
The GDG selected that there was probably no important
uncertainty or variability about how much stakeholders value
the main outcomes. Patients and clinicians would similarly
value the main outcomes: clinically meaningful improvements
in functional status and low rates of major complications. It is
uncertain how much payers would value the main outcomes
given the lack of cost-effectiveness data on operative manage-
ment for mild patients; however, there is also a potential that
surgery may reduce future management costs.
The majority of the GDG (n ¼ 14) felt that the desirable
anticipated effects are probably large. However, several of the
studies included in the systematic review on operative treat-
ment consisted of patients with moderate and severe myelopa-
thy. The results must therefore be interpreted cautiously in the
context of mild DCM; only a single study stratified its sample
by preoperative myelopathy severity. Twelve members of the
GDG were uncertain as to whether the anticipated desirable
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effects were large; their rationale was that the highest quality
study, a randomized controlled trial by Kadanka et al,25,26
reported that there was no difference in mJOA scores between
patients that received operative versus non-operative care. Sim-
ilar to the questions on moderate and severe myelopathy, the
undesirable effects of surgery are probably small due to a low
cumulative incidence of overall complications as well as rates
of reoperation, death, worsening of myelopathy, stroke, and
cardiopulmonary events.
There was a split in the voting as to whether the anticipated
desirable effects were large relative to the undesirable effects
(probably yes ¼ 12, uncertain ¼ 16).
The resources required to surgically manage mild patients
vary based on health care systems and are probably not small.
Furthermore, the cost-effectiveness of surgical treatment is
largely unknown. In patients with moderate myelopathy, sur-
gical intervention may afford significant cost-savings as
patients may be able to return to work following improvement
in functional impairment. It is unlikely that patients with mild
myelopathy and disability pose as much financial burden on
society as those with more advanced disease. The GDG was
uncertain about the impact of a recommendation for surgery on
health inequities and whether this option would be acceptable
to key stakeholders. Furthermore, the option is probably feasi-
ble to implement; potential barriers include access to care,
costs, and an accurate and timely diagnosis of myelopathy.
Given these points, the desirable and undesirable effects are
closely balanced or uncertain; this led to the formation of a
suggestion for operative treatment in patients with mild
myelopathy.
Based on these 2 recommendations, we suggested offering
either surgical intervention or a supervised trial of structured
rehabilitation in patients with mild myelopathy. If patients
experience neurological deterioration during their course of
nonoperative treatment, we strongly recommended conversion
to surgery. A key factor considered for this recommendation is
that both a longer duration of symptoms and more severe mye-
lopathy reduce a patient’s odds of achieving a score16 on the
mJOA18; it is therefore advised that patients with progressive
myelopathy be referred immediately for surgical consultation
regardless of baseline severity in order to halt neurological
deterioration and potentially reverse some of their disability.
Given the evidence that surgery results in clinically significant
gains, we formed a weaker recommendation for operative
intervention in patients who fail to improve following nono-
perative treatment. Since the undesirable and desirable conse-
quences of both nonoperative and operative treatments are
closely balanced, patient preferences must be strongly consid-
ered as patients may be reluctant to undergo surgery for mild
myelopathy, especially if they have not deteriorated over time.
Furthermore, factors that influence the risk-benefit ratio of
either operative or nonoperative management must be weighed
when determining the optimal treatment strategy in these
patients; these include age, comorbidities, duration of symp-
toms, and smoking status. Thus, the GDG recommends a pro-
cess of shared decision making between the surgeon and
patient, with the surgeon providing his or her best estimate of
the risks and benefits of operative and non-operative manage-
ment for that particular individual.
Part 4. Clinical Population: Nonmyelopathic Patients
Without Symptoms of Radiculopathy
Population Description: Nonmyelopathic patients with
imaging evidence of cord compression without signs
or symptoms of radiculopathy
Key Question: Should operative management be used to
treat non-myelopathic patients with evidence of cord
compression without signs or symptoms of
radiculopathy?
Recommendation: We suggest not offering prophylactic
surgery for nonmyelopathic patients with evidence of
cervical cord compression without signs or symptoms
of radiculopathy. We suggest that these patients be
counseled as to potential risks of progression, educated
about relevant signs and symptoms of myelopathy, and
be followed clinically.
Quality of Evidence: No identified evidence; based on
clinical expert opinion
Strength of Recommendation: Weak
Evidence Summary
The GDG agreed that it was important to consider the follow-
ing when developing a recommendation for the treatment of
nonmyelopathic patients with evidence of cord compression:
(1) disease natural history, (2) rates of disease progression and
myelopathy development, and (3) risks of operative interven-
tion. A systematic review was conducted by Wilson et al38 to
determine, in nonmyelopathic patients with radiographic evi-
dence of cervical spinal cord compression, spinal canal narrow-
ing and/or OPLL, (1) the frequency and timing of symptom
development and (2) the clinical, radiographic, and electrophy-
siological predictors of symptom development. This review
focused on longitudinal cohort studies that followed these
patients over time and observed whether they developed signs
and symptoms of myelopathy. We attempted to update this
systematic review; however, there were no studies published
after 2013 that satisfied our inclusion criteria.
Based on the original review, 8% of subjects with evidence of
cord compression or canal stenosis developed myelopathy by 12
months and 22.6% at a median of 44 months.38 This data was
derived from 2 large prospective cohort studies by Bednarik
et al, which did not segregate their population based on whether
patients had clinical evidence of radiculopathy. Furthermore, in
asymptomatic patients with OPLL, the frequency of myelopathy
development ranged from 0% to 61.5% across 3 studies; how-
ever, the overall body of evidence was rated as insufficient for
this finding.38 The cumulative incidence of complications is low
for patients treated surgically for myelopathy; however, studies
have not evaluated rates of complications following prophylactic
surgery in nonmyelopathic patients.
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The GDG agreed that there were no studies that directly
addressed the question of whether operative, nonoperative
treatment or a “wait-and-see” approach should be used to man-
age nonmyelopathic patients with evidence of cord compres-
sion without signs or symptoms of radiculopathy. As a result,
our recommendation will be based on clinical expertise,
resource demand and indirect evidence. Furthermore, the
acceptability of our recommendation and patient preferences
must also be considered as nonmyelopathic individuals may be
hesitant to undergo prophylactic surgery.
Rationale for Recommendation
The GDG agreed that there were no included studies that eval-
uated the comparative effectiveness of operative versus con-
servative treatment in nonmyelopathic patients with evidence
of cord compression without signs or symptoms of radiculo-
pathy. As a result, this recommendation was primarily based on
clinical expertise and on indirect evidence surrounding rates of
myelopathy development.
Given that the main outcome is to prevent the development
of myelopathy, the GDG agreed that there is no important
uncertainty or variability about how much key stakeholders
value this outcome. Based on professional opinion, the GDG
agreed that clinicians, patients, and stakeholders would not
want patients to develop myelopathy due to the associated
impairment and disability, reduced quality of life, costs and
financial burden.
The GDG selected that the anticipated desirable effects of
prophylactic surgery in these patients are probably not large.
Based on the review by Wilson et al,38 only 22.6% of patients
with evidence of cord compression ultimately develop myelo-
pathy; furthermore, this estimate includes all patients, includ-
ing those at a higher risk of disease development. Similar to the
previous three questions, the undesirable effects of surgery are
probably small as the cumulative incidence of complications is
low. This evidence on the safety of surgery was derived from
studies on patients with myelopathy; no studies have explored
complication rates in a nonmyelopathic population. As a result,
the GDG voted that the desirable effects are probably not large
relative to the undesirable effects, especially in patients who
are not at a high risk of developing myelopathy; prophylactic
surgery puts these patients at a risk of complications with little
known benefit.
The resources required to surgically manage these patients
vary based on health care system and are probably not small.
Furthermore, the cost-effectiveness of prophylactic surgical
intervention is largely unknown. Based on professional opin-
ion, the GDG selected that the incremental cost is probably not
small relative to the net benefit. As a result, this option is likely
not acceptable to key stakeholders since prophylactic surgery is
likely costly with limited benefit. The feasibility of this option
is uncertain and likely depends on location; potential barriers
include access to care, long surgical wait times and low surgi-
cal priority compared with myelopathic patients.
As a result of the above explanations, the GDG confirmed
that the undesirable consequences probably outweigh the desir-
able consequences in most settings and that the option of sur-
gery should not be offered in this population.
Part 5. Clinical Population: Nonmyelopathic Patients
With Radiculopathy
Population Description: Nonmyelopathic patients with
imaging evidence of cord compression and clinical
and/or electrophysiological evidence of radiculopathy.
Key Question: Should operative management be used to
treat nonmyelopathic patients with evidence of cord
compression and clinically/electrophysiologically
diagnosed radiculopathy?
Recommendation: Nonmyelopathic patients with cord
compression and clinical evidence of radiculopathy
with or without electrophysiological confirmation are
at a higher risk of developing myelopathy and should
be counselled about this risk. We suggest offering
either surgical intervention or nonoperative treatment
consisting of close serial follow-up or a supervised
trial of structured rehabilitation. In the event of myelo-
pathic development, the patient should be managed
according to the recommendations above.
Quality of Evidence: Low
Strength of Recommendation: Weak
Evidence Summary
This question differs from part 4 because the population of
interest includes nonmyelopathic patients with evidence of
cord compression and radiculopathy. In formulating this rec-
ommendation, the GDG not only focused on the evidence pre-
sented in part 4 but also considered whether clinical and
electrophysiological signs of radiculopathy are important pre-
dictors of myelopathy development.
The systematic review by Wilson et al38 summarized exist-
ing evidence on significant clinical, radiographical and electro-
physiological predictors of symptom development. Important
findings included that (1) the presence of symptomatic radicu-
lopathy was a significant clinical predictor of myelopathy
development in univariate analysis (risk ratio [RR] ¼ 3.0;
95% CI ¼ 2.0-4.4) and (2) prolonged somatosensory (RR ¼
2.9; 95% CI ¼ 1.7-5.1) and motor-evoked potentials (RR ¼
3.2; 95% CI ¼ 1.9-5.6), as well as electromyography evidence
of anterior horn cell lesions (RR¼ 2.4; 95% CI¼ 1.5-3.9) were
significant electrophysiological predictors of myelopathy
development in univariate analysis (low level evidence).38
Furthermore, based on a multivariate analysis, clinically symp-
tomatic radiculopathy (P ¼ .007; moderate level evidence) and
prolonged somatosensory (P ¼ .007; moderate level evidence)
and motor-evoked potentials (P ¼ .033; moderate level evi-
dence) were significantly associated with early (12 months)
myelopathy development.38 Specifically, clinical radiculopa-
thy was diagnosed in 62.5% of patients who developed
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myelopathy by 12 months versus in 26.3% of those who did
not. Furthermore, prolonged somatosensory and motor-evoked
potentials were present in a higher percentage of patients who
developed myelopathy (43.8% and 37.5%, respectively) than
those who did not (16.4% and 16.9%, respectively).
The GDG agreed that there were no studies that directly
addressed the question of whether operative, nonoperative treat-
ment or a “wait-and-see” approach should be used to manage
nonmyelopathic patients with evidence of cord compression and
radiculopathy. As a result, our recommendation will be based on
clinical expertise, resource demand, and indirect evidence.
Furthermore, acceptability of our recommendation and patient
preferences must also be considered, as nonmyelopathic individ-
uals may be hesitant to undergo prophylactic surgery.
Rationale for Recommendation
Similar to part 4, the main outcome driving this recommendation
is the prevention of myelopathy. Unfortunately, there were no
identified studies that discussed the comparative effectiveness of
surgery versus conservative treatment in halting disease devel-
opment. In contrast to question 4, however, it is also important to
consider whether the presence of radiculopathy increases a
patient’s risk of myelopathy; the systematic review provided low
to moderate evidence to answer this question. As a result, the
GDG agreed that the overall certainty of the evidence was low
given that the class II prognostic studies do not directly specify
whether these patients should undergo prophylactic surgery.
Similar to question 4, the GDG confirmed that (1) there is no
important uncertainty or variability about how much key sta-
keholders value the main outcomes (ie, prevention of myelo-
pathy), (2) the resources required for surgery are probably not
small, (3) the incremental cost is probably not small relative to
the net benefit, and (4) the impact of this recommendation on
health inequities and the acceptability and feasibility of this
option are uncertain.
In contrast to question 4, the GDG agreed that the antici-
pated desirable effects are uncertain. Based on the systematic
review by Wilson et al,38 patients with symptomatic and/or
electrophysiological evidence of radiculopathy are at a higher
risk of myelopathy development. This finding may provide a
compelling argument for prophylactic surgery in these patients;
however, there is no evidence to suggest whether the size of the
anticipated desirable effects is large. Similar to the other ques-
tions, the anticipated undesirable effects are probably small
since surgery is associated with a low rate of complications.
These results were derived from studies on myelopathic
patients and should be interpreted with caution. The GDG was
uncertain whether the anticipated desirable effect of preventing
myelopathy outweighed the potential risks associated with sur-
gery. Furthermore, the feasibility of prophylactic surgery is
uncertain and likely varies based on health care system; poten-
tial barriers include access to care, long wait times and low
surgical priority for nonmyelopathic patients.
Considering these factors, the GDG acknowledged that the
anticipated desirable and undesirable effects were closely
balanced or uncertain. As a result, the GDG suggested that
patients should be offered either surgery or a trial of struc-
tured nonoperative treatment. Again, we advocate a shared
decision-making process that takes into account individual
preferences and other factors that may influence surgical risk.
In the case of myelopathy development, the patient should be
treated according to the recommendations proposed in sec-
tions 1 to 3; rapidity of disease onset and disease severity
must be considered when devising an appropriate manage-
ment strategy. This recommendation considered patient pre-
ferences as nonmyelopathic patients might be hesitant to
undergo surgery, as well as the acceptability of this option
to payers and clinicians.
Evidence Gaps and Future Research
Recommendations
This guideline has identified important knowledge gaps in the
literature and areas of future research. These include (1) a lim-
ited understanding of the natural history of DCM; (2) contro-
versy surrounding the comparative effectiveness of surgical
versus nonoperative treatment, especially in patients with mild
myelopathy; (3) a lack of research on structured therapies; (4) a
lack of studies that stratified their sample based on preoperative
disease severity when evaluating the efficacy and safety of non-
operative and surgical management; (5) limited evidence sur-
rounding the cost-effectiveness of surgical and nonoperative
management in patients with varying myelopathy severities; and
(6) uncertainty surrounding patient preferences, acceptability,
and the impact of these recommendations on health inequities,
particularly in a population of patients with mild myelopathy.
Methodological limitations in the existing body of evidence
include (1) the lack of standardized definitions of DCM, mild,
moderate, and severe myelopathy and types of complications;
(2) poorly defined treatment protocols for nonoperative man-
agement; (3) the use of outcome measures with unknown reli-
abilities (eg, mJOA); (4) heterogeneous patient populations and
varying surgical approaches; and (5) loss to follow-up. Further-
more, many of our recommendations considered the associa-
tion between duration of symptoms and surgical outcomes;
however, the reliability of this factor is unknown and is likely
subject to recall bias. Finally, reported rates of disease progres-
sion varied from 20% to 62% and conversion to surgery from
23% to 54%; these wide ranges indicate that the natural history
of DCM is likely variable and differs among patients.
Unfortunately, randomized controlled trials in a surgical
setting are largely unfeasible; it is unethical to deny a patient
surgical intervention when there is not clinical equipoise
between operative and nonoperative treatment. Further pro-
spective observational studies may help to ascertain the effi-
cacy and safety of surgical and non-operative treatment in
patients with mild, moderate, and severe disease. These studies
should use a wide variety of outcome assessment tools, includ-
ing the Graded Redefined Assessment of Strength Sensibility
and Prehension, indices of quality of life (eg, Short-Form 36)
and measures of patient satisfaction.39 Furthermore, in order to
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accurately compare the safety of various treatment options,
there is a need to first standardize definitions of adverse events
and complications. The development of a classification system
will require a thorough systematic review of existing defini-
tions, a modified Delphi process and an evaluation of differ-
ences in functional and quality-of-life outcomes, costs and
satisfaction between patients who do and do not experience a
complication following treatment.
Based on our recommendation for mild patients, it is critically
important to distinguish between patients in a stable disease state
and those at a high risk of deteriorating from mild to moderate
myelopathy. According to several previous studies, risk factors
of neurologic progression include circumferential cord compres-
sion on axial magnetic resonance imaging (MRI); an angular-
edged spinal cord, defined as an acute angled or lateral corner at
one or both sides; greater range of preoperative neck and head
motion; lower segmental lordotic angle and greater percentage
of vertebral slip; segmental instability; and reduced diameter of
the cerebrospinal fluid column.40-44 Future studies are required
to determine important predictors of disease progression and to
better differentiate between types of DCM; genetic or biomarker
studies may help address this knowledge gap.
According to the review by Wilson et al,38 hyperintensity
on a T2-weighted MRI is a significant predictor of myelopa-
thy development (RR ¼ 1.7; 95% CI ¼ 1.0-2.7). Specifically,
T2-hyperintensity was observed in 35.6% of patients who
developed myelopathy versus in 21.4% of those who did not.
For the purpose of this guideline, the GDG decided not to
segregate the asymptomatic population based on presence/
absence of T2-signal change. Future high-quality evidence
on this topic, however, should be incorporated when updating
this guideline.
The cost-effectiveness of surgery and nonoperative treat-
ment is largely unknown and should be evaluated across med-
ical systems worldwide. In doing so, it is important to consider
direct medical and life time costs (including revision surgery)
and health utility gained. Although challenging to evaluate,
resource utilization (eg, primary care visits, prescription drugs)
and indirect costs (eg, forgone productivity, care taker burden)
must also be taken into account.
Beyond the scope of this guideline, other areas of interest in
the field of DCM include (1) the comparative efficacy of var-
ious surgical (eg, laminectomy with fusion vs laminoplasty)
and nonoperative treatments (eg, physiotherapy vs immobiliza-
tion); (2) the impact of neuroprotective agents on treatment
outcomes; (3) an evaluation of the incidence and prevalence
of DCM; (4) the role of advanced imaging techniques in the
diagnosis of myelopathy and prognosis; and (5) an assessment
of the factors that delay either nonoperative or surgical man-
agement in these patients.
Implementation Considerations
It is expected that this guideline will influence clinical practice
and facilitate evidence-based decision making. Dissemination
of the knowledge from this guideline is of critical importance
and will be accomplished at multiple levels:
 Presentation at international spine surgery, neurology,
rheumatology, and primary care meetings
 Scientific and educational courses in symposium format
 Webinar dissemination of information to a broad audi-
ence in an interactive format
 Publication of a focus issue in a peer-reviewed journal
 Submission to the National Guideline Clearinghouse
 AOSpine International Degenerative Knowledge Trans-
lation Forum
Internal Appraisal and External Review of
This Guideline
The vice-chair of the GDG conducted an internal appraisal of
the final guideline using Appraisal of Guidelines for Research
& Evaluation II (AGREE II) standards.45 A multidisciplinary
group of stakeholders, including patients, were invited to exter-
nally review the final draft prior to publication. Additional
details of these processes and a summary of conflict of interests
for external reviewers are found in the accompanying methods
article.
Plans for Updating
The guidelines will be reviewed by the primary sponsor and the
vice-chair at three years to a maximum of five years following
publication. The guideline will be updated when new evidence
suggests the need to modify our recommendations. An earlier
update will be considered if there are changes in (1) the evi-
dence related to harms and benefits, (2) outcomes which would
be considered important for decision making; (3) ranking of
current critical and important outcomes, and (4) available inter-
ventions and resources.46
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